ロード中...
Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still mor...
保存先:
| 出版年: | Int J Mol Sci |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5713435/ https://ncbi.nlm.nih.gov/pubmed/29156610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18112469 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|